Safety pharmacology in focus: New methods developed in the light of the ICH S7B guidance document

Journal of Pharmacological and Toxicological Methods

Volumn 54, Issue 2, 2006, Pages 94-98

  Pugsley, Michael K ^a   Curtis, Michael J ^b  

^a FOREST RESEARCH INSTITUTE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYL SULFOXIDE; HYDROXYETHYLCELLULOSE; MACROGOL 400; NEW DRUG;

CARDIOVASCULAR FUNCTION; DRUG INDUCED DISEASE; DRUG INDUSTRY; DRUG SAFETY; EDITORIAL; EXPERIMENTAL MODEL; HEART MUSCLE CELL; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; NONHUMAN; ORTHOSTATIC HYPOTENSION; PHARMACOLOGICAL SCIENCE; PRACTICE GUIDELINE; PUBLICATION; QT PROLONGATION; SAFETY PHARMACOLOGY; SOLUBILIZATION; TORSADE DES POINTES;

AGED; AGING; ANIMALS; DOGS; ELECTROPHYSIOLOGY; GUIDELINES; HEART RATE; HUMANS; PHARMACEUTICAL PREPARATIONS;

CANIS FAMILIARIS; PRIMATES; RODENTIA;

EID: 33747887173     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2006.05.002     Document Type: Editorial

References (30)

1. Anon (2001). U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Guidance for Industry. S7A: Safety Pharmacology Studies for Human Pharmaceuticals (ICH S7A).
2. Anon. S7B: The Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) By Human Pharmaceuticals (S7B). Federal Register 70 (2005) 61133-61134
3. Bass A.S., Kinter L.B., and Williams P. Origins, practices and future of safety pharmacology. Journal of Pharmacological and Toxicological Methods 49 (2004) 145-151
4. Bass A.S., Vargas H.M., and Kinter L.B. Introduction to Nonclinical safety pharmacology and the safety pharmacology society. Journal of Pharmacological and Toxicological Methods 49 (2004) 141-144
5. Bertaina-Anglade V., Enjuanes E., Morillon D., and Drieu la Rochelle C. The object recognition task in rats and mice: a simple and rapid model in safety pharmacology to detect amnesic properties of a new chemical entity. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.04.001
6. Bridgland-Taylor M.H., Hargreaves A.C., Easter A., Orme A., Harmer A., Henthorn D.C., et al. Validation of Ionworks® HT as a Medium-Throughput, Electrophysiology Assay for hERG Activity. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.02.003
7. Camm A.J. Clinical trial design to evaluate the effects of drugs on cardiac repolarization: current state of the art. Heart Rhythm 2 (2005) S23-S29
8. Cavero I., and Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarization risk of drugs: a critical analysis. Expert Opinion Drug Safety 4 (2005) 509-530
9. Chaves A.A., Keller W.J., O'Sullivan S., Williams M.A., Fitzgerald L.E., McPherson H.E., et al. Cardiovascular Monkey Telemetry: Sensitivity to detect QT interval prolongation. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.03.004
10. Chiang A.Y., Holdsworth D.L., and Leishman D.J. A One-step Approach to the Analysis of the QT Interval in Conscious Telemetrized Dogs. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.02.004
11. Clements-Jewery H., Hearse D.J., and Curtis M.J. Phase 2 ventricular arrhythmias in acute myocardial infarction: a neglected target for therapeutic drug development and safety pharmacology evaluation. British Journal of Pharmacology 145 (2005) 551-564
12. De Clerck F., Van de Water A., D'Aubioul J., Lu H.R., van Rossem K., Hermans A., et al. In vivo measurement of QT prolongation, dispersion and arrhythmogenesis: application to the preclinical cardiovascular safety pharmacology of a new chemical entity. Fundamentals of Clinical Pharmacology 16 (2002) 125-140
13. Du X., Lu D., Daharsh E.D., Yao A., Dewoody R., and Yao J.-A. Dimethyl sulfoxide effects on hERG channels expressed in HEK293 cells. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.03.002
14. Guo L., and Guthrie H. Automated electrophysiology in the preclinical evaluation of drugs for potential QT prolongation. Journal of Pharmacological and Toxicological Methods 52 (2005) 123-135
15. Hanson L.A., Bass A.S., Gintant G., Mittelstadt S.W., Rampe D., and Thomas K. ILSI-HESI Cardiovascular Safety Subcommittee Initiative: Evaluation of Three Non-clinical Models of QT Prolongation. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.05.001
16. Hardy M.E.L., Lawrence C.L., Standen N.B., and Rodrigo G.C. Can optical recordings of membrane potential be used to screen for drug-induced action potential prolongation in single cardiac myocytes?. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.02.013
17. Hata T., Funakami Y., and Itoh E. Effects of AF-DX116 and other muscarinic receptor antagonists on orthostatic hypotension in autonomic imbalanced (SART-stressed) rats. Journal of Pharmacological Sciences 97 (2005) 386-392
18. Hoymann H.G. Invasive and Noninvasive Lung Function Measurements in Rodents. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.04.006
19. Kinter L.B., Siegel P.S., and Bass A.S. New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age. Journal of Pharmacological and Toxicological Methods 49 (2004) 153-158
20. Klumpp A., Trautmann T., Markert M., and Guth B. Optimizing the experimental environment for dog telemetry studies. Journal of Pharmacological Methods (2006) 10.1016/j.vascn.2006.03.010
21. Lee C.H., Strosberg A.M., Roszkowski A.P., and Warren L.A. A model for evaluation of postural hypotension induced by drugs in conscious restrained normotensive rats. Journal of Pharmacological Methods 7 (1982) 15-24
22. Mittelstadt S.W., Adams N.A., and Spruell R.D. Age Dependent Effects on Cisapride Induced QTc Prolongation in the Isolated Guinea Pig Heart. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.02.011
23. Murphy D.J., Renninger J.P., and Ju H. A model of orthostatic hypotension in the conscious monkey using lower body negative pressure. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.03.001
24. Pals D.T., and Orley J. A nonhuman primate model for evaluating the potential of antihypertensive drugs to cause orthostatic hypotension. Journal of Pharmacological Methods 9 (1983) 183-192
25. Pestel S., Martin H.-J., Maier G.-M., and Guth B. Effect of Commonly Used Vehicles on Gastrointestinal, Renal and Liver Function in Rats. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.02.006
26. Pugsley M.K. An overview of some pharmacological methods used in safety pharmacology studies. Proceedings of the Western Pharmacology Society 47 (2004) 18-22
27. Shi X., Wray D.W., Formes K.J., Wang H.W., Hayes P.M., O-Yurvati A.H., et al. Orthostatic hypotension in aging humans. American Journal of Physiology. Heart and Circulatory Physiology 279 (2000) H1548-H1554
28. Sponer G., Mannesmann G., Bartsch W., and Dietmann K. A method for evaluating postural hypotension in conscious rabbits as a model to predict effects of drugs in man. Journal of Pharmacological Methods 5 (1981) 53-58
29. Valentin J.-P., Bass A.S., Atrakchi A., Olejniczak K., and Kannosuke F. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A. Journal of Pharmacological and Toxicological Methods 52 (2005) 22-29
30. Vormberge T., Hoffmann M., and Himmel H. Safety pharmacology Assessment of drug-induced QT-Prolongation in Dogs with Reduced Repolarization Reserve. Journal of Pharmacological and Toxicological Methods (2006) 10.1016/j.vascn.2006.03.011